Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects

The effect of the oral direct thrombin inhibitor ximelagatran and its active form, melagatran, on thrombin generation was investigated in vitro and ex vivo using a thrombin generation assay. In-vitro thrombin generation was triggered in human platelet-poor plasma by the addition of tissue factor, and the endogenous thrombin potential (ETP) was measured. The ETP IC50 values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 μmol/l and 0.06 IU/ml, respectively. In contrast to dalteparin, melagatran increased the time-to-thrombin peak in a concentration-dependent manner. ETP was also studied ex vivo in platelet-poor plasma collected from healthy male subjects (n = 54) at pre-dose and 2 h post-dose, with ximelagatran (60 mg) orally, dalteparin (120 IU/kg) subcutaneously, or control (water) orally. After ximelagatran or dalteparin administration, the time-to-thrombin peak was prolonged by 41 and 95%, and the ETP was decreased by 61 and 77%, respectively. Thus, melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, efficiently delays and inhibits the generation of thrombin in plasma both in vitro and ex vivo.

[1]  B. Eriksson,et al.  Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393 , 1996, The Lancet.

[2]  A. Guha,et al.  Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. , 1992, Biochemistry.

[3]  S. Schulman,et al.  A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I , 2003, Journal of thrombosis and haemostasis : JTH.

[4]  J. Badimón,et al.  Thrombin in arterial thrombosis. , 1994, Haemostasis.

[5]  B. Eriksson,et al.  Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial , 2002, The Lancet.

[6]  K. Wiklund,et al.  Low-molecular-weight heparin during instability in coronary artery disease , 1996 .

[7]  J. McVey,et al.  Tissue factor pathway. , 1994, Bailliere's best practice & research. Clinical haematology.

[8]  P. Petersen,et al.  Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation , 2003 .

[9]  J. Rak,et al.  The benefit‐to‐risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model , 2003, Journal of thrombosis and haemostasis : JTH.

[10]  H. Hemker,et al.  Continuous Registration of Thrombin Generation in Plasma, Its Use for the Determination of the Thrombin Potential , 1993, Thrombosis and Haemostasis.

[11]  J. Stürzebecher,et al.  The Ability of Thrombin Inhibitors to Reduce the Thrombin Activity Generated in Plasma on Extrinsic and Intrinsic Activation , 1997, Thrombosis and Haemostasis.

[12]  J. Dawes.  Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. , 1990, Acta chirurgica Scandinavica. Supplementum.

[13]  A. Rezaie,et al.  Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. , 2001, Blood.

[14]  H. Hemker,et al.  In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma , 1989 .

[15]  D. Prasa,et al.  Inhibition of Thrombin Generation in Plasma by Inhibitors of Factor Xa , 1997, Thrombosis and Haemostasis.

[16]  H. Hemker,et al.  A Computer Assisted Method to Obtain the Prothrombin Activation Velocity in Whole Plasma Independent of Thrombin Decay Processes , 1986, Thrombosis and Haemostasis.

[17]  H. Hemker,et al.  Conjectures and Refutations on the Mode of Action of Heparins , 1999, Pathophysiology of Haemostasis and Thrombosis.

[18]  J. Deinum,et al.  The interaction between captured human thrombin and antithrombin studied by surface plasmon resonance, and the effect of melagatran , 2002 .

[19]  C. Francis,et al.  Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty , 2002, Annals of Internal Medicine.

[20]  M. Wolzt,et al.  Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects , 2002, Thrombosis and Haemostasis.

[21]  P. A. von dem Borne,et al.  Factor XI and Protection of the Fibrin Clot against Lysis – a Role for the Intrinsic Pathway of Coagulation in Fibrinolysis , 1998, Thrombosis and Haemostasis.

[22]  S. Pehrsson,et al.  Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes , 1998, Thrombosis and Haemostasis.

[23]  Ulf Bredberg,et al.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects , 2003, European Journal of Clinical Pharmacology.

[24]  J. Badimón,et al.  Blood-borne tissue factor: another view of thrombosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Bush.  Argatroban, A Selective, Potent Thrombin Inhibitor , 1991 .

[26]  P. Petersen,et al.  Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. , 2003, Journal of the American College of Cardiology.

[27]  H. Hemker,et al.  In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. , 1989, Blood.

[28]  B. Eriksson,et al.  A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I , 2002, Thrombosis and Haemostasis.

[29]  P. Björquist,et al.  Determination of the kinetic constants of tissue factor/factor VII/factor VIIA and antithrombin/heparin using surface plasmon resonance. , 1997, Thrombosis research.

[30]  T. Lindhout,et al.  The Anticoagulant Mechanism of Action of Recombinant Hirudin (CGP 39393) in Plasma , 1990, Thrombosis and Haemostasis.

[31]  Marie Davidian,et al.  Nonlinear Models for Repeated Measurement Data , 1995 .

[32]  G. Broze.  Tissue factor pathway inhibitor and the current concept of blood coagulation , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[33]  M. Wolzt,et al.  Comparison of the Effects of Different Low Molecular Weight Heparins on the Hemostatic System Activation In Vivo in Man , 1997, Thrombosis and Haemostasis.

[34]  P. Sandset,et al.  Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[35]  C. Colwell,et al.  Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. , 2001, Archives of internal medicine.

[36]  Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. , 1996, Lancet.